Cerevance said its Phase 3 trial of oral solengepras met its primary endpoint by reducing Parkinson’s patients’ daily “off” time in people experiencing motor fluctuations despite levodopa. The study randomized 341 participants to placebo or two once-daily solengepras doses. Safety signals were generally mild to moderate, with no serious adverse events reported in the higher-dose arm. The company positioned solengepras as a dopamine-sparing add-on therapy that inhibits a protein linked to motor coordination rather than directly targeting dopamine itself. Investigators cited changes in “on time” and other motor and sleep-related surveys as secondary support. With the result, Cerevance is moving toward regulatory discussions about potential approval, betting that an oral, non-dopaminergic mechanism could reduce dyskinesia risk relative to standard escalation pathways.